Related Experiment Video
Updated: Aug 23, 2026
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies
1Department of Internal Medicine, University of Texas Health Science Center, Texas Heart Institute, Houston, Texas.
Insights
Thrombolytic therapy improves outcomes for heart attack patients, but faster reperfusion and preventing artery reocclusion are key challenges. New agents and antiplatelet combinations require testing to enhance efficacy and safety.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Thrombolytic therapy significantly reduces mortality and preserves ventricular function in acute myocardial infarction (MI).
- Current limitations include slow thrombolysis rates and high rates of infarct-related artery reocclusion.
- Optimizing reperfusion and preventing reocclusion remain critical goals in MI management.
Purpose of the Study:
- To identify and improve thrombolytic regimens for faster reperfusion and reduced reocclusion.
- To evaluate novel third-generation thrombolytic agents and combination therapies.
- To assess the safety and efficacy of adjunctive antiplatelet strategies.
Main Methods:
- Investigating third-generation thrombolytic agents and their mutants.
- Testing combinations of antiplatelet drugs with thrombolytic agents.
- Exploring various antiplatelet classes, including thromboxane A(2) inhibitors, serotonin antagonists, thrombin antagonists, and platelet receptor antibodies.
Main Results:
- Focus on developing strategies to shorten the time from ischemia onset to reperfusion.
- Emphasis on preventing reocclusion of the infarct-related artery.
- Need for therapies that reduce reocclusion without significantly increasing bleeding risk.
Conclusions:
- Further research is needed on advanced thrombolytic agents and combination therapies.
- Adjunctive antiplatelet strategies show promise in improving outcomes.
- Balancing reperfusion efficacy with bleeding risk is crucial for optimal patient care.
Abstract:
Thrombolytic therapy has had a major impact on reducing mortality and preserving segmental ventricular function in patients with Q-wave infarcts who are treated early. Despite this substantial progress, a number of problems remain, most of which are related to the rate at which thrombolysis occurs and the risk of reocclusion of the infarct-related artery. Efforts need to be aimed at identifying and improving thrombolytic regimens that are capable of shortening the interval between the onset of ischemia and the achievement of reperfusion, as well as preventing reocclusion. Third-generation thrombolytic agents, including mutants of thrombolytic agents that are currently available, and different combinations of antiplatelet and thrombolytic regimens need to be tested for their abilities to reduce the time to thrombolysis and to delay or prevent reocclusion, without markedly increasing the risk of bleeding. Such adjunctive therapy might be provided by a variety of antiplatelet drugs, including combinations of thromboxane A(2) synthesis inhibitors and receptor antagonists with serotonin receptor antagonists; thrombin antagonists; possibly platelet-activating factor antagonists; or monoclonal antibodies to the platelet receptors responsible for platelet attachment, platelet aggregation, or both.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:29Venous Thrombosis III: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management